esmo 2014: inhibition of parp, angiogenesis and immune checkpoints for ovarian cancer management
Published 9 years ago • 289 plays • Length 6:18Download video MP4
Download video MP3
Similar videos
-
2:38
assessing the role of parp inhibitors and immunotherapy in ovarian cancer
-
1:26
esmo 2014: phase ii study 19 quality of life study of olaparib in ovarian cancer
-
3:12
parp-inhibitors: a new generation of cancer drugs
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
5:19
mechanisms of parp inhibition: a mode of targeted cancer treatment
-
3:44
the future role of parp inhibition in ovarian cancer
-
28:24
chair's take: latest and emerging evidence of parp inhibitors in ovarian cancer management
-
4:44
expert report on survival data from pivotal trials with parp inhibitors for brca-mut. ovarian cancer
-
58:12
enhancing personalized medicine in ovarian cancer: advances in parp inhibition and novel modalities
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
6:36
role of parp inhibition in ovarian cancer
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
23:32
role of parp inhibitor in ovarian cancer dr. thomas herzog
-
8:44
parp inhibition in ovarian cancer
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
1:41
parp inhibitors at the crossroads in ovarian cancer: 2022 esmo florida